Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology ...
October 27 2020 - 09:00AM
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company
focused on innovative therapeutics to treat orphan autoimmune and
inflammatory diseases where the complement and/or leukotriene
systems are implicated, today announces that it will be presenting
a poster during the 29th European Academy of Dermatology and
Venereology (EADV) Congress being held virtually October 28 –
November 1, 2020. The presentation will be posted onto Akari’s
website.
The poster presentation will describe the safety
and efficacy data from Akari’s Phase II clinical trial of nomacopan
in adult patients with mild to moderate bullous pemphigoid.
Details of the presentation are as follows:
- Title: A Phase II
Clinical Trial of Safety and Efficacy of Nomacopan (rVA576) in
Adult Mild-to-moderate Bullous Pemphigoid Patients
- Date/Time: October
29, 2020 at 12:00 CET (7:00 a.m. EDT)
- Location: EADV
Virtual Meeting. Registration is required to participate:
https://eadvvirtualcongress.org/registration/
About Bullous Pemphigoid
(BP)BP is a severe orphan autoimmune inflammatory
blistering skin disease with no approved treatments in the U.S. and
Europe. This disease of the elderly is primarily treated with
steroids and immunosuppressants for six months plus which bring
with them deleterious side effects and an approximately three-fold
increase in mortality in the BP treated population. The prevalence
of BP is over 100,000 patients in US and Europe.
In BP patients there is evidence that both terminal
complement activation (via complement component C5) and the lipid
mediator leukotriene B4 (LTB4) have a central role in driving the
disease. Ex vivo data in BP patients, published in the August
2019 edition of JCI Insight, showed a pronounced accumulation
of LTB4 and C5 and its activation products in the inflamed skin of
BP patients. This underlies the rationale for treatment with
nomacopan which is a unique bifunctional inhibitor of both C5 and
LTB4 and a range of downstream cytokines. In addition to BP, the
Company believes this unique mode of action underpins the activity
of nomacopan across the Company’s other target conditions –
TMA-HSCT, COVID pneumonia and ophthalmology as well as other
emerging clinical indications.
About Akari TherapeuticsAkari
is a biopharmaceutical company focused on developing inhibitors of
acute and chronic inflammation, specifically for the treatment of
rare and orphan diseases, in particular those where the complement
(C5) or leukotriene (LTB4) systems, or both complement and
leukotrienes together, play a primary role in disease progression.
Akari's lead drug candidate, nomacopan (formerly known as
Coversin), is a C5 complement inhibitor that also independently and
specifically inhibits leukotriene B4 (LTB4) activity.
Cautionary Note Regarding Forward-Looking
StatementsCertain statements in this press release
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. You should not
place undue reliance upon the Company’s forward looking statements.
Except as required by law, the Company undertakes no obligation to
revise or update any forward-looking statements in order to reflect
any event or circumstance that may arise after the date of this
press release. These forward-looking statements reflect our current
views about our plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to us and on assumptions we have made. Although we believe that our
plans, intentions, expectations, strategies and prospects as
reflected in or suggested by those forward-looking statements are
reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by
a variety of risks and factors that are beyond our control. Such
risks and uncertainties for our company include, but are not
limited to: needs for additional capital to fund our operations,
our ability to continue as a going concern; uncertainties of cash
flows and inability to meet working capital needs; an inability or
delay in obtaining required regulatory approvals for nomacopan and
any other product candidates, which may result in unexpected cost
expenditures; our ability to obtain orphan drug designation in
additional indications; risks inherent in drug development in
general; uncertainties in obtaining successful clinical results for
nomacopan and any other product candidates and unexpected costs
that may result therefrom; difficulties enrolling patients in our
clinical trials; our ability to enter into collaborative,
licensing, and other commercial relationships and on terms
commercially reasonable to us; failure to realize any value of
nomacopan and any other product candidates developed and being
developed in light of inherent risks and difficulties involved in
successfully bringing product candidates to market; inability to
develop new product candidates and support existing product
candidates; the approval by the FDA and EMA and any other similar
foreign regulatory authorities of other competing or superior
products brought to market; risks resulting from unforeseen side
effects; risk that the market for nomacopan may not be as large as
expected; risks associated with the impact of the outbreak of
coronavirus; risks associated with the SEC investigation; inability
to obtain, maintain and enforce patents and other intellectual
property rights or the unexpected costs associated with such
enforcement or litigation; inability to obtain and maintain
commercial manufacturing arrangements with third party
manufacturers or establish commercial scale manufacturing
capabilities; the inability to timely source adequate supply of our
active pharmaceutical ingredients from third party manufacturers on
whom the company depends; unexpected cost increases and pricing
pressures and risks and other risk factors detailed in our public
filings with the U.S. Securities and Exchange Commission, including
our most recently filed Annual Report on Form 20-F filed with the
SEC. Except as otherwise noted, these forward-looking statements
speak only as of the date of this press release and we undertake no
obligation to update or revise any of these statements to reflect
events or circumstances occurring after this press release. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release.
Investor Contact:
Peter VozzoWestwicke+1 (443)
213-0505peter.vozzo@westwicke.com
Media Contact:
Sukaina Virji / Lizzie SeeleyConsilium
Strategic Communications+44 (0)20 3709
5700Akari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2023 to Mar 2024